Mutations in mitochondrial DNA-encoded 
Introduction
Defects in the mitochondrial oxidative phosphorylation system (OXPHOS) are associated with several human diseases. The lack of ATP supply caused by the OXPHOS dysfunction affects primarily high-energy demand tissues such as brain, skeletal muscle and heart resulting in severe pathology. These defects are caused by genetic alteration of either nuclear or mitochondrial genomes [1] . [1] . The mutations can cause instability of tRNA, affect interaction with the translation machinery or cause misincorporation of amino acids ultimately affecting OXPHOS function and ATP supply [2, 3] .
Although the nuclear DNA encodes for the majority of mitochondrial proteins, the mitochondrial DNA (mtDNA) encodes for 13 subunits, 22 tRNAs and 2 rRNAs. Pathogenic mutations in most of these mitochondrial genes have been reported. Mutations in tRNA genes are particularly common in the patient population and cause a generalized defect in mitochondrial protein synthesis
We and others have demonstrated that OXPHOS defects with a residual ATP generating capacity can be at least partially compensated by increasing mitochondrial mass through enhanced mitochondrial biogenesis [4] [5] [6] [7] . This mitochondrial proliferation can be achieved by activation of peroxisome proliferator-activated receptor (PPAR) gamma coactivator-1␣ (PGC-1␣), the key regulator of mitochondrial biogenesis [8] . PGC-1␣ interacts with PPARs, as well as with other nuclear factor including oestrogen related receptor ␣ and the nuclear respiratory factors (NRF1 and NRF2) to increase transcription of mitochondrial proteins. One of the target genes is mtDNA transcription factor A (TFAM), which modulates mtDNA transcription and mtDNA replication [9] . PGC-1␣ expression and activity is controlled by the PPARs [9, 10] as well as by AMP-protein activated kinase (AMPK) and Sirt1 [11] . Many agonists have been identified that activate these proteins, such as bezafibrate (PPAR) , resveratrol (Sirt1) and AminoimidazolCarboxamide-Ribonucleoside (AICAR) and metformin (AMPK). [4, 7, 12, 13] . We showed that bezafibrate can enhance OXPHOS activity (normalized to tissue mass) in a mouse model of mitochondrial myopathy caused by an isolated cytochrome c oxidase (COX) defect [7] .
Many of them have been shown to induce mitochondrial proliferation both in vivo and in vitro and thus offer the potential of pharmacological intervention
We also previously showed that adenoviral-induced PGC-1␣/␤ expression and the associated increased mitochondrial biogenesis partially relieve single respiratory chain enzyme defects in cultured cells from patients with mitochondrial disorders [5] . Bastin et al. demonstrated that bezafibrate offers a pharmacological option to increase mitochondrial mass and achieve similar effects in patient cell lines harbouring mutations in nuclear genes [4] .
Here 
Materials and methods

Cell lines
Previously described transmitochondrial cybrids were used (Table 1) 
RT-PCR experiments
ATP synthesis and levels
ATP synthesis in DMSO-or bezafibrate-treated cells was measured as described previously [14] . ATP levels were determined after extraction from cells using perchloric acid as described [14] . ATP 
Measurement of mitochondrial enzyme activities
Mitochondrial enzyme complex activities were measured spectrophotometrically in cells using a DU-640 spectrophotometer (Beckman Instruments, Inc., Fullerton, CA, USA) as described elsewhere [15] [15] . All assays were performed at 37ЊC (except the CS at 30ЊC).
Western blots analysis
Western blot analysis was performed as described [5] . Antibodies 
Mitochondrial labelling
Mitochondrial protein labelling was performed in transmitochondrial cybrids grown in the presence of bezafibrate or DMSO as described [17] . Fig. 2A and B) Fig. 2A and B Fig. 3A and B (Fig. 1A) , we observed increases of 1.5-2.5-fold in CS activity in both control and mutant cells lines when grown in bezafibrate (Fig. 3C) Fig. 3A and B) and decreased steady-state levels of OXPHOS enzymes (Fig. 3D-F) . When grown in bezafibrate, the endogenous levels of some OXPHOS subunits were increased in homogenates from MELAS (Fig. 3D), MERRF (Fig. 3E) and W72 cybrids (Fig.  3F) . Surprisingly, not all peptides were increased or increased proportionally, suggesting that the functional improvement may involve not only an increase in mitochondrial biogenesis, but also other pathways. We did observe an increase in the flavoprotein of succinate dehydogenase (SDHA) and the VDAC1 in bezafibrate grown mutant cells (Fig. 3D-F ) mutant cells (Fig. 4A, B) . Mutant cells grown in bezafibrate had significantly increased levels of the affected tRNAs, up to 50% of the level of DMSO-treated control cells (Fig. 4A) S-methionine labelling of mitochondrial proteins (Fig. 4C) .
Results
We have studied the effect of bezafibrate administration in four different transmitochondrial cybrid cell lines, each of them carrying a homoplasmic mutation in mtDNA encoded tRNAs (
Fig. 1 Bezafibrate induces a metabolic shift in cultured cells. (A) Relative expression of PGC-1␣ and TFAM in mutant and control cell lines grown in bezafibrate-supplemented media. Cells grown in media with vehicle (DMSO) were used as a reference (n ϭ 3 and bars represent S.D.). P Ͻ 0.001 for all samples. (B) Lactate concentration of bezafibrate and DMSO-treated mutant and control cell lines in media after 24 hrs growth (n ϭ 3 and bars represent S.D.). (C) Glucose consumption of mutant and control cell lines after 24 hrs growth (n ϭ 3 and bars represent S.D.). (D) Growth curves of MELAS and MERRF mutant cells treated with bezafi-
Fig. 3 Bezafibrate increases overall OXPHOS enzyme activity and steady state levels by increasing mitochondrial mass. (A) and (B) COX and combined CI ϩ III activity in bezafibrate and DMSO-treated mutant and control cell lines (n ϭ 3 and bars represent S.D.). (C) CS activity in bezafibrate and DMSO-treated mutant and control cell lines (n ϭ 3 and bars represent S.D.). (D)-(E) Western blot analysis of bezafibrate and DMSO-treated mutant and control lines. Antibodies against ND39 (complex I), SDH (flavoprotein of complex II), COXI and COXIV (complex IV), ATPase subunit ␤ (complex V) and VDAC1 (outer membrane pro
Suppressors of tRNA mutation G5703A have increased PGC-1␣ levels
Our group reported several years ago a suppression of mitochondrial tRNA mutation associated with changes in the nuclear background [24] . These [25] . Additionally, PPARs target genes coding for mitochondrial proteins [4, 26] [26] . Given the board spectrum of target genes it is likely that these effects are not related solely to triglycerides and HDL levels, but rather a more global metabolic re-programming. Metabolic remodelling in response to fasting or exercise in liver and muscle is known to involve PGC-1␣ and PPAR [27] . [5, 7] . All these findings in cell lines and murine models with different mitochondrial defects imply that increasing mitochondrial mass and thereby boosting overall residual OXPHOS capacity can benefit different classes of mitochondrial defects. Induced mitochondrial proliferation might hence be a novel therapeutic strategy for mitochondrial disorders in general.
